Dr Reddys Laboratories Ltd Corporate Actions

Dr. Reddy’s Receives Two USFDA Observations for New York API Manufacturing Plant

 Copy Link

Issuance of a Form 483 occurs when an investigator(s) has observed any conditions that in their judgment may constitute violations of the FD&C Act and related Acts.

Dr Reddy’s Q4 Profit Jumps 22% to ₹1,594 Crore

 Copy Link

The board has recommended a final dividend of ₹8 per equity share for FY 2024–25

Top Stocks for Today - 12th May 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: Adani Power, Dr Reddy's, and Bank of India, etc.

Dr. Reddy’s Laboratories Sells 14 ANDAs to Senores Pharma

 Copy Link

Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.

Top Stocks for - 27th February 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.

Dr Reddy’s Hyderabad API Unit Gets USFDA VAI Classification

 Copy Link

Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore. 

Dr Reddy’s Laboratories Q3 net profit zooms ~3%

 Copy Link

The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.

Top Stocks for Today - 24th January 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

Top Stocks for today - 6th December 2024

 Copy Link

Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.

Dr Reddy’s launches first immuno-onco drug in India

 Copy Link

Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.